ReNeuron presents further positive data from ExoPr0
ReNeuron Group
3.38p
17:30 11/04/24
0.00%
0.00p
Cell-based therapeutics developer ReNeuron Group announced on Monday that it was presenting further new positive preclinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at the American Society for Exosomes and Microvesicles 2017 annual meeting in San Francisco.
FTSE AIM All-Share
755.28
17:14 26/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
0.10%
22.78